文献速递肿瘤 PET/CT

68Ga标记肽CK2用于体内NRP-1表达PET显像的临床前评价

Preclinical evaluation of 68 Ga-labeled peptide CK2 for PET imaging of NRP-1 expression in vivo.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-02-06

本研究设计并合成靶向神经纤毛蛋白-1(NRP-1)的PET示踪剂[68Ga]Ga-NOTA-PEG4-CK2,在乳腺癌MDA-MB-231等细胞及荷瘤模型中评价其靶向性、敏感性和特异性。结果显示该示踪剂放射化学产率>98%、放射化学纯度>95%、对NRP-1亲和力KD=25.39±1.65 nM,可灵敏检测NRP-1表达动态变化。

要点

  • [68Ga]Ga-NOTA-PEG4-CK2放射化学产率>98%、放射化学纯度>95%,对NRP-1亲和力KD=25.39±1.65 nM。
  • 注射后10分钟MDA-MB-231荷瘤最高摄取4.16±0.67%ID/mL,显著高于NCI-H1299荷瘤的1.03±0.19%ID/mL。
  • SB-203580处理可抑制MDA-MB-231中NRP-1表达,该示踪剂可灵敏检测此动态变化。

核心结论

  • 成功制备有前景的NRP-1靶向PET示踪剂[68Ga]Ga-NOTA-PEG4-CK2,在监测NRP-1表达动态变化方面显示显著特异性和敏感性,可为NRP-1相关癌症早期诊断和预后评估提供有价值信息。

研究设计与样本

  • 临床前研究:通过计算机模拟和小尺度热泳(MST)设计NRP-1靶向肽NOTA-PEG4-CK2,并用68Ga标记制备示踪剂。
  • 评价放射化学产率、放射化学纯度、摩尔活度、脂水分配系数和稳定性。
  • 通过体外细胞摄取实验、体内PET显像及阻断实验研究靶向特异性。
  • 在体外和体内研究示踪剂监测化学药物诱导NRP-1表达动态变化的敏感性。
  • 进行离体生物分布、放射自显影、蛋白质印迹和免疫荧光染色研究特异性。

主要发现

  • [68Ga]Ga-NOTA-PEG4-CK2放射化学产率>98%、稳定性好(放射化学纯度>95%)、对NRP-1高亲和力(KD=25.39±1.65 nM)。
  • 体外细胞摄取实验显示示踪剂可特异性结合NRP-1阳性MDA-MB-231细胞(2小时1.04±0.04%),而非NRP-1阴性NCI-H1299细胞(0.43±0.05%)。
  • 体内PET显像示注射后10分钟MDA-MB-231荷瘤最高摄取4.16±0.67%ID/mL,显著高于NCI-H1299荷瘤的1.03±0.19%ID/mL。
  • 注射后60分钟MDA-MB-231荷瘤肿瘤/肌肉摄取比5.22±0.18,高于NCI-H1299荷瘤的1.07±0.27。
  • 用非放射性前体NOTA-PEG4-CK2预处理的MDA-MB-231荷瘤注射后10分钟肿瘤摄取低至1.67±0.38%ID/mL。

关键数值与推荐

  • [68Ga]Ga-NOTA-PEG4-CK2放射化学产率>98%、放射化学纯度>95%、KD=25.39±1.65 nM。
  • MDA-MB-231细胞2小时摄取1.04±0.04%,NCI-H1299细胞0.43±0.05%。
  • 注射后10分钟MDA-MB-231荷瘤摄取4.16±0.67%ID/mL vs NCI-H1299荷瘤1.03±0.19%ID/mL。
  • 注射后60分钟MDA-MB-231荷瘤肿瘤/肌肉比5.22±0.18 vs NCI-H1299荷瘤1.07±0.27。
  • NOTA-PEG4-CK2预处理MDA-MB-231荷瘤注射后10分钟摄取1.67±0.38%ID/mL。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Neuropilin-1 (NRP-1) is a multifunctional protein involved in a variety of biological processes such as angiogenesis, tumorigenesis and immunomodulation. It was usually overexpressed in many cancer cell lines and correlated with poor prognosis of breast cancer. Positron emission tomography (PET) is an advanced imaging technique for detecting the function and metabolism of tumor-associated molecules in real time, dynamically, quantitatively and noninvasively. To improve the level of early diagnosis and evaluate the prognosis of breast cancer, an NRP-1 targeting peptide-based tracer [68 Ga]Ga-NOTA-PEG4-CK2 was designed to sensitively and specifically detect the NRP-1 expression in vivo via PET imaging. METHODS: In silico modeling and microscale thermophoresis (MST) assay were carried out to design the NRP-1 targeting peptide NOTA-PEG4-CK2, and it was further radiolabeled with 68 Ga to prepare the tracer [68 Ga]Ga-NOTA-PEG4-CK2. The radiochemical yield (RCY), radiochemical purity (RCP), molar activity (Am), lipid-water partition coefficient (Log P) and stability of [68 Ga]Ga-NOTA-PEG4-CK2 were assessed. The targeting specificity of the tracer for NRP-1 was investigated by in vitro cellular uptake assay and in vivo PET imaging as well as blocking studies. The sensitivity of the tracer in monitoring the dynamic changes of NRP-1 expression induced by chemical drug was also investigated in vitro and in vivo. Ex vivo biodistribution, autoradiography, western blot, and immunofluorescence staining were also performed to study the specificity of [68 Ga]Ga-NOTA-PEG4-CK2 for NRP-1. RESULTS: [68 Ga]Ga-NOTA-PEG4-CK2 was designed and synthesized with high RCY (> 98%), high stability (RCP > 95%) and high affinity to NRP-1 (KD = 25.39 ± 1.65 nM). In vitro cellular uptake assay showed that the tracer [68 Ga]Ga-NOTA-PEG4-CK2 can specifically bind to NRP-1 positive cancer cells MDA-MB-231 (1.04 ± 0.04% at 2 h) rather than NRP-1 negative cancer cells NCI-H1299 (0.43 ± 0.05%). In vivo PET imaging showed the maximum tumor uptake of [68 Ga]Ga-NOTA-PEG4-CK2 in MDA-MB-231 xenografts (4.16 ± 0.67%ID/mL) was significantly higher than that in NCI-H1299 xenografts (1.03 ± 0.19%ID/mL) at 10 min post injection, and the former exhibited higher tumor-to-muscle uptake ratio (5.22 ± 0.18) than the latter (1.07 ± 0.27) at 60 min post injection. MDA-MB-231 xenografts pretreated with nonradioactive precursor NOTA-PEG4-CK2 showed little tumor uptake of [68 Ga]Ga-NOTA-PEG4-CK2 (1.67 ± 0.38%ID/mL at 10 min post injection). Both cellular uptake assay and PET imaging revealed that NRP-1 expression in breast cancer MDA-MB-231 could be effectively suppressed by SB-203580 treatment and can be sensitively detected by [68 Ga]Ga-NOTA-PEG4-CK2. Ex vivo analysis also proved the high specificity and sensitivity of [68 Ga]Ga-NOTA-PEG4-CK2 for NRP-1 expression in MDA-MB-231 xenografts. CONCLUSION: A promising NRP-1 targeting PET tracer [68 Ga]Ga-NOTA-PEG4-CK2 was successfully prepared. It showed remarkable specificity and sensitivity in monitoring the dynamic changes of NRP-1 expression. Hence, it could provide valuable information for early diagnosis of NRP-1 relevant cancers and evaluating the prognosis of cancer patients.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Liu Q, Cai S, Ye J, et al. Preclinical evaluation of 68 Ga-labeled peptide CK2 for PET imaging of NRP-1 expression in vivo. Eur J Nucl Med Mol Imaging. 2024. PMID: 38319321. doi:10.1007/s00259-024-06632-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。